

Review of: "Lymphoma: Potential Viral Antagonism between HTLV-1 and JCV Associated with Increased Survival Time"

Omid Salahi Ardekani¹

¹ Shiraz University of Medical Sciences

Potential competing interests: No potential competing interests to declare.

In this article, the author investigates the intriguing notion of viral antagonism between HTLV-1 and JCV among lymphoma patients. However, despite the captivating nature of this topic, the article lacks compelling evidence to substantiate this hypothesis. These are my suggestions:

1) Improve Introduction Content: The introduction should provide a thorough overview of the significance of Human T-lymphotropic virus 1 (HTLV-1), including details about the virus itself, associated diseases, treatment strategies, and its pivotal role in oncology. Expounding on these aspects will offer readers a solid foundation for understanding the subsequent discussion on HTLV-1 and its potential interaction with the John Cunningham virus (JCV).

2) Enhance Methodology Explanation: Enhance the description of the methodology employed in the comparative analysis of JCV and HTLV-1 proteins. This elaboration should encompass a delineation of the tools or software utilized for analysis, specification of parameters considered during analysis, and elucidation of any inherent limitations of the approach. Such clarification will enhance the transparency of the study's methodology, fostering a deeper comprehension of the analytical processes employed.

3) The discussion section fails to adequately reference previous studies, which is essential for providing a comprehensive analysis. It is imperative for the discussion to thoroughly describe and analyze relevant previous research